MRI TECHNIQUES FOR SMALL ANIMAL NEURO-IMAGING

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究建立了一种转基因小鼠模型（P301 S，PS19系）， 阿尔茨海默病（AD）的tau蛋白病。神经病理学的组织学特征显示 突触丢失、海马小胶质细胞增生、丝状tau内含物和最终神经元 损失本研究的目的是使用磁共振非侵入性地表征这些小鼠 磁共振成像（MRI），有可能将这些技术转化为临床环境， AD的诊断以及跟踪治疗反应。各种MRI技术可能是 适用于这项任务，包括扩散张量MRI（DTI），高分辨率MRI，动脉自旋标记 (ASL)灌注MRI、T1 p MRI和化学交换饱和转移（CEST）成像。这 项目目前正处于人员培训和初步扫描的早期阶段。体内 小型啮齿动物神经成像的方案需要优化。所得测量 并将图像与组织学和免疫组织化学表征进行比较。是我们 希望为小型啮齿动物成像提供广泛使用的MRI技术，以及发现 AD的非侵入性生物标志物

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A transgenic mouse model (P301S, PS19 line) was recently developed for studying the characteristic tauopathy of Alzheimer's Disease (AD). Histological characterization of the neuropathology shows signs of synapse loss, hippocampal microgliosis, filamentous tau inclusions, and eventual neuron loss. The goal of this study is to characterize these mice non-invasively using magnetic resonance imaging (MRI), with the potential to translate these techniques into the clinical setting for early diagnosis of AD, as well as for tracking treatment response. A variety of MRI techniques may be suited for this task, including diffusion tensor MRI (DTI), high resolution MRI, arterial spin labeling (ASL) perfusion MRI, T1p MRI, and chemical exchange saturation transfer (CEST) imaging. This project is currently at an early stage of personnel training and preliminary scanning. In-vivo protocols for small rodent neurological imaging will need to be optimized. Resulting measurements and images will be compared with histology and immunohistochemistry characterization. It is our hope to provide widely accessible MRI techniques for small rodent imaging, as well as the discovery of non-invasive biomarkers for AD